Needham & Company
View Older Stories
-
After-Hours Movers: Danaher Jumps on Spinoff Plans, Arconic Sinks on Lower Outlook
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $25 at Needham & Company on FDA Approval for BBS
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $40 at Needham & Company
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $45 at Needham & Company
-
Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
-
Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $50 at Needham & Company
-
Companies with NDRs 10/16
-
Rhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference
-
Rhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference
-
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Rhythm Pharmaceuticals (RYTM) Prices 8.108M Share Common Offering at $18.50/Sh
-
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
-
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
-
Rhythm Pharmaceuticals (RYTM) Announces Proposed $150M Share Offering
-
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
-
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
-
Needham & Company Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Following Positive Data
-
Rhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
-
Rhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
-
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $42 at Needham & Company
-
Rhythm Pharmaceuticals (RYTM) Prices 5.73M Shares at $26.42
-
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
-
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
-
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
-
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $36 at Needham & Company; 'POMC Phase 3 Data Slip to 3Q19, but LEPR Ahead of Schedule'
-
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March
-
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March
-
Needham & Company Starts Rhythm Pharmaceuticals (RYTM) at Buy
-
Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Rhythm Pharmaceutical (RYTM) IPO Opens Up 37%
-
Rhythm Pharmaceuticals (RYTM) Prices 7.05M Share IPO at $17/Sh
-
Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering